OncoMed: Annual Report 2015 (OncoMed) - Mar 12, 2016 - Anticipated expiry of patents in US and ex-US related to composition of matter and method of use in 2029; Anticipated expiry of patents in US and ex-US related to certain uses of brontictuzumab in 2025 or 2031; Anticipated expiry of patents relating to brontictuzumab, certain of its uses and/or related biomarkers between 2025 to 2035
Anticipated patent expiry • Oncology
|